Stockreport

Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient

Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares  (CANF) 
NASDAQ:AMEX Investor Relations: ir.canfite.com
PDF RAMAT GAN, Israel, March 26, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company developing a pipeline of prop [Read more]